Analysis of risk factors and outcomes in psychiatric inpatients with tardive dyskinesia: A nationwide case-control study
- PMID: 31193370
- PMCID: PMC6526243
- DOI: 10.1016/j.heliyon.2019.e01745
Analysis of risk factors and outcomes in psychiatric inpatients with tardive dyskinesia: A nationwide case-control study
Abstract
Objective: To analyze comorbidities and outcomes in patients with tardive dyskinesia (TD) during psychiatric inpatient management.
Methods: We conducted a case-control study using the Nationwide Inpatient Sample. It included 77,022 adult inpatient admissions for mood disorders and schizophrenia. Cases had a secondary diagnosis of TD, and controls without TD were matched for age. Multivariable logistic regression was used to generate odds ratio (OR).
Results: Majority of TD patients were older age adults (50-64 years; 40%), and were in nearly equal proportions of men and women. African Americans had two-fold higher odds of TD. TD patients had a higher likelihood for cardio-metabolic comorbidities-obesity (OR 1.61, 95% CI 1.481-1.756), hypertension (OR 1.78, 95% CI 1.635-1.930) and diabetes (OR 1.54, 95% CI 1.414-1.680) compared to controls. They also had 1.5-fold increased risk of comorbid drug abuse. Patients with schizophrenia and bipolar disorder (depressive) had four-fold higher odds of TD. TD patients had about six-fold higher odds of severe morbidity. They had a higher likelihood of extended hospitalization stay by 6.36 days (95% CI 6.174-6.550) and higher cost by $20,415 (95% CI 19537-21293) compared to controls.
Conclusion: Psychiatric inpatients with TD have greater severity of illness, and those with schizophrenia and bipolar disorders are at highest risk. Presence of TD portends poor hospital outcomes and need for higher acute inpatient care.
Keywords: Psychiatry.
Similar articles
-
Medical and Psychiatric Comorbidities in Bipolar Disorder: Insights from National Inpatient Population-based Study.Cureus. 2019 Sep 12;11(9):e5636. doi: 10.7759/cureus.5636. Cureus. 2019. PMID: 31700739 Free PMC article.
-
The burden of tardive dyskinesia secondary to antipsychotic medication use among patients with mental disorders.Curr Med Res Opin. 2019 Jul;35(7):1205-1214. doi: 10.1080/03007995.2019.1569871. Epub 2019 Feb 15. Curr Med Res Opin. 2019. PMID: 30638073
-
Hospital utilization rates following antipsychotic dose reductions: implications for tardive dyskinesia.BMC Psychiatry. 2018 Sep 24;18(1):306. doi: 10.1186/s12888-018-1889-2. BMC Psychiatry. 2018. PMID: 30249218 Free PMC article.
-
Systematic reviews of the effectiveness of day care for people with severe mental disorders: (1) acute day hospital versus admission; (2) vocational rehabilitation; (3) day hospital versus outpatient care.Health Technol Assess. 2001;5(21):1-75. doi: 10.3310/hta5210. Health Technol Assess. 2001. PMID: 11532238 Review.
-
Clinical risk factors for the development of tardive dyskinesia.J Neurol Sci. 2018 Jun 15;389:21-27. doi: 10.1016/j.jns.2018.02.012. Epub 2018 Feb 5. J Neurol Sci. 2018. PMID: 29439776 Review.
Cited by
-
Identifying the diagnostic gap of tardive dyskinesia: an analysis of semi-structured electronic health record data.BMC Psychiatry. 2025 Apr 21;25(1):407. doi: 10.1186/s12888-025-06780-w. BMC Psychiatry. 2025. PMID: 40259324 Free PMC article.
-
Region-Wise Distribution of Schizophrenia With Cannabis Abuse and Medication Non-Compliance in the United States: A Nationwide Analysis of 51,975 Hospitalizations.Cureus. 2020 May 2;12(5):e7936. doi: 10.7759/cureus.7936. Cureus. 2020. PMID: 32494541 Free PMC article.
-
Assesment of Risk Factors for Tardive Dyskinesia.Psychopharmacol Bull. 2020 Jul 23;50(3):36-46. Psychopharmacol Bull. 2020. PMID: 32733110 Free PMC article.
-
Use and Discontinuation Rates of Long-Acting Injectable Antipsychotics Between Race/Ethnicity in Older Adults Using Medicaid Databases.J Am Geriatr Soc. 2025 May;73(5):1454-1461. doi: 10.1111/jgs.19386. Epub 2025 Feb 5. J Am Geriatr Soc. 2025. PMID: 39907048 Free PMC article.
-
The Clinical and Economic Burden of Tardive Dyskinesia in Israel: Real-World Data Analysis.J Clin Psychopharmacol. 2022 Sep-Oct 01;42(5):454-460. doi: 10.1097/JCP.0000000000001597. Epub 2022 Aug 20. J Clin Psychopharmacol. 2022. PMID: 36018237 Free PMC article.
References
-
- Arisco J.P., Holden L.D. Prevalence of tardive dyskinesia in private psychiatric inpatients. Tex. Med. 1989;85(1):25–28. - PubMed
-
- Bailey L.G., Maxwell S., Brandabur M.M. Substance abuse as a risk factor for tardive dyskinesia: a retrospective analysis of 1,027 patients. Psychopharmacol. Bull. 1997;33(1):177–181. - PubMed
-
- Ballesteros J., Gonzalez-Pinto A., Bulbena A. Tardive dyskinesia associated with higher mortality in psychiatric patients: results of a meta-analysis of seven independent studies. J. Clin. Psychopharmacol. 2000;20(2):188–194. - PubMed
-
- Brasic J.R. 2018. Tardive Dyskinesia.https://emedicine.medscape.com/article/1151826-overview Retrieved from.
-
- Browne S., Roe M., Lane A., Gervin M., Morris M., Kinsella A.…Callaghan E.O. Quality of life in schizophrenia: relationship to sociodemographic factors, symptomatology and tardive dyskinesia. Acta Psychiatr. Scand. 1996;94(2):118–124. - PubMed
LinkOut - more resources
Full Text Sources